Jose Juves

Bio:

José brings more than 20 years of diverse experience spanning communications, investor relations, general management and commercial expertise in the biopharmaceutical industry. At Dyne, he leads the company’s investor relations, communications, and patient advocacy efforts. Before Dyne, he was the head of corporate and patient affairs at X4 Pharmaceuticals where he led the communications for the company’s first FDA approval and commercial launch in the United States. He has held similar roles at Takeda Pharmaceuticals and Wave Life Sciences. Prior to Wave Life Sciences, José was at Biogen, where he worked in communications and public affairs in the US and Europe, managing communications for commercial and pipeline products, investor relations, business development and public policy. His tenure at Biogen also included eight years in a variety of commercial leadership roles including global brand lead for a $2 billion product and General Manager for Argentina, Chile and Uruguay. Prior to joining the biopharmaceutical industry, Jose worked in a variety of Massachusetts government roles. He earned a BA from Tufts University and serves on the board of trustees for the Community Charter School of Cambridge.